Skip to main
NNVC
NNVC logo

NanoViricides (NNVC) Stock Forecast & Price Target

NanoViricides (NNVC) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nanoviricides Inc demonstrates a promising financial trajectory due to the extension of its line of credit until late December 2025, which enhances its cash flow and liquidity position during critical clinical development phases. The company's management is optimistic about the transformative potential of its antiviral platform, particularly with NV-387 showing considerable effectiveness against various influenza strains, thus positioning it favorably in the competitive landscape of antiviral treatments. Furthermore, the exploration of innovative therapies targeting herpes, RSV, and smallpox suggests a diversified pipeline that could lead to future revenue generation, reinforcing a positive outlook on the company's financial health and growth potential.

Bears say

Nanoviricides Inc. has reported a negative cash outflow of $1.7 million for the December quarter, indicating increased operational expenditures that are projected to rise further as the company engages in clinical trials between July 2024 and June 2025. This anticipated higher cash burn underscores concerns regarding the need for future capital raising, which may lead to equity dilution for existing shareholders. Additionally, the inherent development risks associated with Nanoviricides' technology, compounded by the typical higher risk profile of biotech stocks, further contribute to a cautious outlook on the company's stock performance and the viability of its drug candidates.

NanoViricides (NNVC) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NanoViricides and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NanoViricides (NNVC) Forecast

Analysts have given NanoViricides (NNVC) a Strong Buy based on their latest research and market trends.

According to 1 analysts, NanoViricides (NNVC) has a Strong Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NanoViricides (NNVC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.